Scholar Rock Holding Corp (SRRK)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.27B
Last updated: Nov 17, 2026 at 11:06 AM ET
Scholar Rock Holding Corp (SRRK) Earnings: Report Dates and Results
Scholar Rock Holding (SRRK) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Scholar Rock Holding reported EPS of -$0.81, above the -$0.87 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SRRK has an expected report date of Mar 1, 2027.
SRRK Earnings Call
The latest SRRK earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 34 quarters below that had an estimate, SRRK beat 14, missed 18 and matched 2. The widest gap in the table came in the quarter ended Mar 31, 2018, when EPS landed 104.00% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.81 | -$0.87 | -$0.94 - -$0.73 | +6.90% | Beat | N/A | 12 | 1 up, 0 down | Nov 10, 2026 | $570000 |
| Jun 30, 2026 | -$0.84 | -$0.84 | -$0.94 - -$0.77 | 0.00% | In line | N/A | 11 | 3 up, 3 down | Aug 6, 2026 | N/A |
| Mar 31, 2026 | -$0.83 | -$0.78 | -$0.91 - -$0.62 | -6.41% | Miss | N/A | 13 | 1 up, 0 down | May 7, 2026 | N/A |
| Dec 31, 2025 | -$0.88 | -$0.90 | -$1.07 - -$0.57 | +2.04% | Beat | N/A | 11 | 2 up, 7 down | Mar 3, 2026 | N/A |
| Sep 30, 2025 | -$0.90 | -$0.84 | -$1.00 - -$0.57 | -7.14% | Miss | N/A | 9 | N/A | Nov 14, 2025 | N/A |
| Jun 30, 2025 | -$0.98 | -$0.67 | -$0.73 - -$0.57 | -46.27% | Miss | N/A | 5 | 0 up, 0 down | Aug 6, 2025 | N/A |
| Mar 31, 2025 | -$0.67 | -$0.71 | -$0.93 - -$0.54 | +5.63% | Beat | N/A | 4 | 0 up, 3 down | May 14, 2025 | N/A |
| Dec 31, 2024 | -$0.61 | -$0.63 | -$0.67 - -$0.58 | +2.99% | Beat | N/A | 5 | 1 up, 4 down | Feb 27, 2025 | N/A |
| Sep 30, 2024 | -$0.66 | -$0.59 | -$0.65 - -$0.54 | -11.86% | Miss | N/A | 9 | 0 up, 0 down | Nov 12, 2024 | N/A |
| Jun 30, 2024 | -$0.60 | -$0.59 | -$0.72 - -$0.57 | -1.69% | Miss | N/A | 9 | 0 up, 0 down | Aug 8, 2024 | N/A |
| Mar 31, 2024 | -$0.59 | -$0.51 | -$0.60 - -$0.45 | -15.69% | Miss | N/A | 9 | 0 up, 0 down | May 7, 2024 | N/A |
| Dec 31, 2023 | -$0.50 | -$0.49 | -$0.54 - -$0.45 | -2.04% | Miss | N/A | 8 | 0 up, 0 down | Mar 19, 2024 | $11.66M |
| Sep 30, 2023 | -$0.53 | -$0.51 | -$0.68 - -$0.46 | -3.92% | Miss | N/A | 8 | 1 up, 0 down | Nov 7, 2023 | N/A |
| Jun 30, 2023 | -$0.47 | -$0.55 | -$0.79 - -$0.48 | +14.55% | Beat | N/A | 7 | 0 up, 0 down | Aug 9, 2023 | N/A |
| Mar 31, 2023 | -$0.49 | -$0.52 | -$0.81 - -$0.48 | +5.77% | Beat | N/A | 6 | 0 up, 0 down | May 9, 2023 | N/A |
| Dec 31, 2022 | -$0.46 | -$0.57 | -$0.77 - -$0.49 | +19.30% | Beat | N/A | 8 | 0 up, 0 down | Mar 7, 2023 | $33.19M |
| Sep 30, 2022 | -$0.55 | -$0.64 | -$0.87 - -$0.43 | +14.06% | Beat | N/A | 8 | 0 up, 0 down | Nov 14, 2022 | N/A |
| Jun 30, 2022 | -$1.06 | -$1.01 | N/A | -4.95% | Miss | N/A | N/A | 2 up, 0 down | Aug 8, 2022 | N/A |
| Mar 31, 2022 | -$0.21 | -$0.62 | -$1.16 - -$0.16 | +66.13% | Beat | N/A | 7 | 0 up, 0 down | May 16, 2022 | $33.19M |
| Dec 31, 2021 | -$0.97 | -$1.00 | -$1.19 - -$0.92 | +3.00% | Beat | N/A | 5 | N/A | Mar 7, 2022 | $4.05M |
| Sep 30, 2021 | -$1.02 | -$0.76 | N/A | -34.21% | Miss | N/A | 5 | N/A | Nov 9, 2021 | $5.46M |
| Jun 30, 2021 | -$0.84 | -$0.73 | -$0.86 - -$0.66 | -15.07% | Miss | N/A | 5 | N/A | Aug 10, 2021 | $4.59M |
| Mar 31, 2021 | -$0.76 | -$0.65 | -$0.78 - -$0.62 | -16.92% | Miss | N/A | 5 | N/A | May 13, 2021 | $4.71M |
| Dec 31, 2020 | -$0.79 | -$0.63 | -$0.74 - -$0.57 | -25.40% | Miss | N/A | 6 | N/A | Mar 9, 2021 | $3.44M |
| Sep 30, 2020 | -$0.79 | -$0.50 | -$0.63 - -$0.48 | -58.00% | Miss | N/A | 4 | N/A | Nov 9, 2020 | $3.04M |
| Jun 30, 2020 | -$0.65 | -$0.46 | N/A | -41.30% | Miss | N/A | 5 | N/A | Aug 7, 2020 | $3.90M |
| Mar 31, 2020 | -$0.58 | -$0.02 | -$0.46 - $0.30 | N/A | N/A | N/A | 5 | N/A | May 7, 2020 | $5.03M |
| Dec 31, 2019 | -$0.39 | -$0.53 | -$0.65 - -$0.50 | +26.42% | Beat | N/A | 4 | N/A | Mar 12, 2020 | $7.57M |
| Sep 30, 2019 | -$0.55 | -$0.41 | -$0.52 - $0.02 | -34.15% | Miss | N/A | 4 | N/A | Nov 12, 2019 | $4.77M |
| Jun 30, 2019 | -$0.48 | -$0.31 | N/A | -54.84% | Miss | N/A | 4 | N/A | Aug 14, 2019 | $5.04M |
| Mar 31, 2019 | -$0.42 | -$0.50 | -$0.61 - -$0.38 | +16.00% | Beat | N/A | 4 | N/A | May 14, 2019 | $3.11M |
| Dec 31, 2018 | -$0.43 | -$0.45 | N/A | +4.44% | Beat | N/A | 4 | N/A | Mar 18, 2019 | N/A |
| Sep 30, 2018 | -$0.44 | -$0.56 | -$1.17 - -$0.44 | +21.43% | Beat | N/A | 4 | N/A | Nov 8, 2018 | N/A |
| Jun 30, 2018 | -$0.58 | -$0.58 | -$1.39 - -$0.43 | 0.00% | In line | N/A | 4 | N/A | Aug 8, 2018 | N/A |
| Mar 31, 2018 | -$1.02 | -$0.50 | N/A | -104.00% | Miss | N/A | 1 | N/A | May 24, 2018 | N/A |
| Mar 31, 2017 | -$0.19 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.43, after -$2.46 the year before. It was -$2.66 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.43 | N/A |
| Dec 31, 2024 | -$2.46 | N/A |
| Dec 31, 2023 | -$1.99 | N/A |
| Dec 31, 2022 | -$2.28 | N/A |
| Dec 31, 2021 | -$3.59 | N/A |
| Dec 31, 2020 | -$2.81 | N/A |
| Dec 31, 2019 | -$1.84 | N/A |
| Dec 31, 2018 | -$2.66 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,300 words across 17 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,259 | 17 | |
| 2026Q2 | Jun 30, 2026 | 7,035 | 18 | |
| 2026Q1 | Mar 31, 2026 | 8,301 | 17 | |
| 2025Q4 | Dec 31, 2025 | 7,759 | 19 | |
| 2025Q3 | Sep 30, 2025 | 7,065 | 14 | |
| 2025Q2 | Jun 30, 2025 | 6,140 | 13 | |
| 2025Q1 | Mar 31, 2025 | 6,287 | 16 | |
| 2024Q4 | Dec 31, 2024 | 6,205 | 8 |
2026Q3 Earnings Call
Opening remarks
Laura Ekas Vice President, Investor Relations Good morning. I'm Laura Ekas, Vice President, Investor Relations at Scholar Rock. With me today are David Hallal, Chairman and Chief Executive Officer; Keith Woods, Chief Operating Officer; Akshay Vaishnaw, President of R&D; and Vikas Sinha, Chief Financial Officer. During today's call, David will provide introductory remarks and a business overview. Keith will discuss the U.S. launch of ISEMBYLD and global commercial readiness. Akshay will review our regulatory and R&D progress, and Vikas will provide a financial update. We will then open the call for questions. Before we begin, I'd like to remind you that during this call, we will be making various statements about Scholar Rock's expectations, plans and prospects that constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any future date. I encourage you to go to the Investors and Media section of our website for our most up-to-date SEC statements and filings. With that, I'd like to turn the call over to David. David?
David Hallal Chairman and Chief Executive Officer Thank you, Laura, and good morning. Thanks to everyone for joining our third quarter earnings call. Today, Scholar Rock is operating from a position of great strength, and we are executing with focus, discipline and urgency. In mid-September, we received FDA approval well ahead of our PDUFA date for ISEMBYLD, the world's first and only muscle-targeted therapy for children and adults living with SMA. And following approval, we immediately commenced our U.S. launch. In early October, we resubmitted our apitegromab MAA in Europe for the treatment of children and adults with SMA. The application, which now includes our alternate fill/finish facility, has been validated, and we expect a CHMP opinion in the first half of 2027. In early November, we submitted our apitegromab JNDA in Japan, 2 months ahead of our guidance. The application was accepted under priority review and, pending approval, we anticipate a launch in Japan near year-end 2027. In Q3, we also commenced dosing in our Phase II FORGE study, evaluating apitegromab in people living with FSHD. And finally, this morning, we announced we have entered into a definitive agreement to monetize our priority review voucher for $205 million, which will further strengthen our financial position to fund our ambitious global commercial and R&D growth initiatives. With this, let me turn to our U.S. approval and launch of ISEMBYLD. ISEMBYLD is a highly innovative myostatin inhibitor and the world's first and only muscle-targeted therapy approved for patients with SMA.
Frequently Asked Questions About SRRK
When is Scholar Rock Holding's next earnings date?
Scholar Rock Holding's next earnings report is expected for Mar 1, 2027.
Did SRRK beat earnings estimates last quarter?
Yes. Scholar Rock Holding reported EPS of -$0.81 for the quarter ended Sep 30, 2026, above the -$0.87 estimate, a 6.90% surprise.
What EPS do analysts expect from SRRK next quarter?
The consensus EPS estimate for Scholar Rock Holding for the quarter ending Dec 31, 2026 is -$0.74 from 20 analysts, with estimates from -$0.98 to $0.87.
How often does SRRK beat earnings estimates?
Scholar Rock Holding beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -5.28%.
SRRK pages: Overview, Earnings, Forecast, Financials, Competitors